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ORIGINAL ARTICLEMesenchymal Stromal Cell-Derived PTX3
Promotes Wound Healing via Fibrin
Remodeling
Claudia Cappuzzello1, Andrea Doni2, Erica Dander1, Fabio Pasqualini2, Manuela Nebuloni3,
Barbara Bottazzi2, Alberto Mantovani2, Andrea Biondi1, Cecilia Garlanda2 and Giovanna D’Amico1Although mesenchymal stromal cells (MSCs) can promote wound healing in different clinical settings, the un-
derlying mechanism of MSC-mediated tissue repair has yet to be determined. Because a nonredundant role of
pentraxin 3 (PTX3) in tissue repair and remodeling has been recently described, here we sought to determine
whether MSC-derived PTX3 might play a role in wound healing. Using a murine model of skin repair, we found
that Ptx3-deficient (Ptx3/) MSCs delayed wound closure and reduced granulation tissue formation compared
with wt MSCs. At day 2, confocal microscopy revealed a dramatic reduction in green fluorescent protein (GFP)-
expressing Ptx3/ MSCs recruited to the wound, where they appeared to be not only poorly organized in
bundles but also scattered in the extracellular matrix. These findings were further confirmed by quantitative
biochemical analysis of GFP content in wound extracts. Furthermore, Ptx3/ MSC-treated skins displayed
increased levels of fibrin and lower levels ofD-dimer, suggesting delayedfibrin-richmatrix remodeling compared
with control skins. Consistently, both pericellular fibrinolysis and migration through fibrin were found to be
severely affected in Ptx3/MSCs. Overall, our findings identify an essential role of MSC-derived PTX3 in wound
repair underscoring the beneficial potential of MSC-based therapy in the management of intractable wounds.
Journal of Investigative Dermatology (2016) 136, 293-300; doi:10.1038/JID.2015.346INTRODUCTION
Optimal wound healing requires a well-orchestrated integra-
tion of biological and molecular events regulating cell migra-
tion, proliferation, and extracellular matrix (ECM) remodeling
(Martin, 1997; Singer and Clark, 1999). As wound healing
impairment represents a major health problem, the cellular
andmolecular events required for appropriate repair constitute
a major research focus. In this regard, the presence of mesen-
chymal stromal cells (MSCs) in both epidermal and dermal
compartments (Sellheyer and Krahl, 2010; Toma et al., 2001),
and their critical role in skin renewal (Badiavas et al., 2003)
have prompted many investigators to utilize MSCs for the
treatment of nonhealing wounds resulting from burns (Bey
et al., 2010), diabetes (Falanga et al., 2007), and Crohn’s dis-
ease (Ciccocioppo et al., 2011). Mounting evidence suggests
that MSC paracrine signaling, rather than MSC differentiation,
might constitute the main regulatory pathway involved in
MSC-enhanced tissue repair (Hocking and Gibran, 2010; Liu
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the signaling pathway mediating this process are not
completely understood.
Pentraxin 3 (PTX3) is an essential component of the hu-
moral arm of innate immunity (Bottazzi et al., 2010),
involved in the resistance against microorganisms (Lu et al.,
2008) and inflammation (Deban et al., 2010). It is well
established that key activators of the inflammatory and
reparative response after tissue injury, such as proin-
flammatory cytokines and Toll-like receptors, induce PTX3
production in different cell types, including stromal cells
(Bottazzi et al., 2010; Dinarello, 2009; Medzhitov, 2008).
Moreover, the secretome of adipose tissueederived MSCs
contains high levels of PTX3 during the early stages of mes-
engenic differentiation (Chiellini et al., 2008).
A more recent study has shown that PTX3 plays a nonre-
dundant protective role in the regulation of tissue repair and
remodeling (Doni et al., 2015). Doni et al. found that in
acidic conditions occurring during tissue damage and repair,
PTX3 bound fibrinogen and/or fibrin and plasminogen and
increased plasmin-mediated pericellular fibrinolysis. In this
regard, murine models of tissue damage showed a correlation
between PTX3 deficiency and increased fibrin deposition and
persistence followed by augmented collagen deposition.
Furthermore, Ptx3-deficient remodeling cells showed alter-
ations in the organization and migration throughout the
provisional fibrin matrix. Interestingly, throughout the wound
healing process, among other remodeling cells, stromal cells
of mesenchymal origin appeared to be the major source of
PTX3 (Doni et al., 2015).
On the basis of this initial characterization and the above-
mentioned findings, we sought to determine the functionalestigative Dermatology. www.jidonline.org 293
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294role of PTX3 during tissue repair and remodeling exerted by
bone marrow (BM)-derived MSCs. For this purpose, we
analyzed the effect of Ptx3-deficient (Ptx3/) MSCs on a
murine model of excisional cutaneous wound healing.
To our knowledge, this study describes a previously unre-
ported mechanism of MSC-derived PTX3 in wound closure,
underscoring the therapeutic potential of MSCs-based stra-
tegies in the treatment of nonhealing wounds.
RESULTS
In vitro characterization of BM-derived Ptx3L/L and wt
MSCs
We first evaluated basal or cytokine-induced PTX3 produc-
tion in the supernatants of wt MSCs by ELISA. As shown in
Figure 1a, detectable levels of PTX3 were found in the culture
medium of unstimulated MSCs (0.22  0.13 ng/ml of protein;
mean  SEM; n ¼ 4). Exposure of MSCs to IL-1b, tumor
necrosis factor-a, and IL-6 for 24 hours led to a robustFigure 1. In vitro characterization of BM-derived Ptx3L/L and wt MSCs. (a) Box
(st) wt MSCs. *P  0.05, versus unexposed MSCs (un). (b) PTX3 deficiency in Ptx3
Representative FACS analysis (n ¼ 3) of Ptx3/ and wt MSCs (dotted line, contro
accumulation (left panel; Oil Red-O staining) and mineralization (right panel; A
medium (þ). (e) Unstimulated MSC proliferation. (f) Expression of CD106, CD54,
line: antigen expression of unstimulated or stimulated MSC, respectively; black-d
bone marrow; MSC, mesenchymal stromal cell; PTX3, pentraxin 3; Ptx3/, Ptx
Journal of Investigative Dermatology (2016), Volume 136induction of PTX3 protein expression in the supernatant
(33.34  11.68 ng/ml of protein; mean  SEM, compared
with unexposed MSCs). As expected, the expression of PTX3
was undetectable in both unexposed and cytokine-stimulated
Ptx3/ MSCs, as shown in Figure 1b.
To investigate the role of PTX3 in MSC-mediated wound
healing, we isolated Ptx3/MSCs from BM of Ptx3 knockout
mice and extensively characterized them for their pheno-
typical and functional properties before using them in vivo.
Both Ptx3/ and wt MSCs were found to be strongly positive
for stromal celleassociated antigens such as CD29, CD90,
and ScaI, and negative for hematopoietic myeloid and
lymphoid markers, as assessed by FACS analysis (Figure 1c).
When cultured in adipogenic and osteogenic medium, both
Ptx3/ and wt MSCs differentiated into adipocytes and
osteoblasts (Figure 1d).
Next, we sought to determine the spontaneous (unsti-
mulated) proliferation of both Ptx3/ and wt MSC lines. Weplot showing the PTX3 content in supernatants (n ¼ 4) of cytokine-stimulated
/MSCs and increased expression in the wt MSCs on cytokine exposure. (c)
l; black line, cells with antibody). (d) Microscopic view showing the lipid drop
lizarin Red-S staining) after 3 weeks of culture in control () and induction
and CD274 after 24 hours of stimulation with IFN-g and TNF-a. Black or red
otted line, isotype Ab. (g) Inhibition of lymphocyte proliferation by MSCs. BM,
3-deficient; TNF-a, tumor necrosis factor-a.
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not differ significantly from that of wt MSCs (n ¼ 3)
throughout the entire time course, as assessed by the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide (MTT) assay (Figure 1e). Furthermore, we determined
the expression of molecules involved in the immunomod-
ulatory properties of MSCs by FACS analysis. On 24 hours of
tumor necrosis factor-a and IFN-g treatment, both Ptx3/
and wt MSCs displayed similar patterns of expression levels
of adhesion molecules, such as CD106/VCAM-1 and CD54/
ICAM-1, as well as CD274/programmed death ligand-1
(Figure 1f).
Finally, we assessed the ability of Ptx3/ MSCs to affect
lymphocyte proliferation induced by phytohemagglutinin. As
shown in Figure 1g, Ptx3/ MSCs (n ¼ 4) inhibited
lymphocyte proliferation in a dose-dependent manner simi-
larly to wt MSCs (n ¼ 4).
PTX3 deficiency in MSCs affects skin wound healing
To examine the effect of PTX3 deficiency in MSCs on wound
closure, mice were wounded on the back and immediately
treated with Ptx3/ or wt MSCs. The analysis of wound
closure kinetics revealed that, consistent with previous
studies (Javazon et al., 2007; Sasaki et al., 2008; Wu et al.,
2007), wt MSCs increased the percentage of wound closure
(52.01  1.7 vs. 23.6  5.07; values represent mean  SEM
percentage wound closure by wt MSC-treated vs. vehicle-
treated wounds, respectively, at day 3 after wound creation)
(Figure 2a and b). In contrast, Ptx3/MSCs showed impaired
ability to accelerate wound closure compared with wt cells
throughout the entire time course (P  0.01 up to day 9 and P
 0.05 from day 10 to day 14) (Figure 2a and b). Furthermore,
Ptx3/ MSCs failed to enhance wound closure versus sham
since day 2 up to day 9 after wounding, and only a minoreffect was observed on days 10 and 11 (P  0.05 at days 10
and 11).
To perform histological or immunohistochemical staining,
wounds with surrounding skin were excised from both MSC-
treated and sham mice. At day 7 after wounding, computer-
assisted morphometric analysis of hematoxylin and eosin
staining revealed a severe reduction of the granulation tissue
area in wounds treated with Ptx3/ MSCs (5.4  0.56 vs.
8.0  0.99 mm2; values represent the mean  SEM granu-
lation tissue area of Ptx3/ MSCs- vs. wt MSCs-treated
wounds) (Figure 2c and d). Furthermore, as PTX3 modu-
lates the inflammatory response (Deban et al., 2010), we
quantified the immune cell subpopulations recruited to the
wound bed of MSC-treated and vehicle-treated skins.
Throughout the wound healing process, we did not observe
any difference in recruitment of both granulocytes (GR-1þ
cells) and macrophages and/or monocytes (F4/80þ cells)
(data not shown). Similarly, capillary density, assessed by
CD31 staining at 2, 7, and 14 days after wounding, did not
differ among groups (data not shown).
Defective recruitment of Ptx3L/L MSCs at the wound site
To ascertain whether the impaired healing capacity of
Ptx3/ MSCs was attributable to their defective recruitment
to the sites of injury, we analyzed the amount of these cells
in the wound bed at day 2 after wounding. To this end, a
new set of wound healing experiments were performed
treating the wounds with GFP-expressing (GFPþ) MSCs or
vehicle alone (sham). Subsequently, GFPþ MSC distribution
in wound sections, as well as PTX3 expression, was deter-
mined by confocal microscopy. As shown in Figure 3a,
numerous GFPþ wt MSCs were detected in the entire
wound area at day 2. These cells were organized in aligned
bundles that collectively invaded the wound bed and theFigure 2. Effect of Ptx3L/L MSCs on
wound healing. (a) Kinetics of
excisional wound closure in mice
treated with Ptx3/ (n ¼ 33), wt
MSCs (n ¼ 45) and vehicle (sham)
(n ¼ 15), respectively. Values
represent the mean percentage of
wound closure  SEM (n ¼ 5
experiments), **P  0.01, and *P 
0.05, Ptx3/ versus wt MSCs. $P 
0.05, Ptx3/ MSCs versus sham. (b)
Representative digital photographs of
full-thickness excisional wounds taken
immediately or at different time points
after wounding. (c) Representative
photographs of histology at day 7
(20 magnification). c, clot; gt,
granulation tissue. Bar ¼ 1,000 mm.
(d) Graph showing computer-assisted
morphometrical analysis of the
granulation tissue area (from 7 to 12
samples analyzed) at day 7. *P  0.05,
Ptx3/ MSCs versus wt MSCs or wt
MSCs versus sham. MSC,
mesenchymal stromal cell; Ptx3/,
Ptx3-deficient.
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Figure 3. Analysis of Ptx3L/L MSC
recruitment to the wounded skin and
colocalization of PTX3 expression
with the pericellular matrix of MSCs.
(a, b) Confocal images of wt (n ¼ 5)
and Ptx3/ (n ¼ 5) MSCs entering the
clot (c) and wound bed (wb) (day 2).
(a) 10; (b) 40. (a, b) left panels:
merged images; right panels: staining
of nucleus (blue, upper and lower
panels) and PTX3 (cyan, upper panel),
or nucleus and GFP (green, lower
panel). Yellow arrowheads:
localization of PTX3 at the pericellular
matrix of MSCs invading the wound
bed. (b) right: close-up of squared
areas in (b) left. Bar ¼ 200 mm (a) or
50 mm (b). (c) Western blotting and
(d) densitometry of GFP and b-actin
expression in wound extracts (day 2).
Data are fold change mean  SEM of
four independent samples. Lysates
from 1 sham wound and GFPþ cells
(c) were loaded as controls. **P 
0.01, versus wt MSCs. GFP, green
fluorescent protein; MSC,
mesenchymal stromal cell; PTX3,
pentraxin 3; Ptx3/, Ptx3-deficient.
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296clot area. High levels of PTX3 protein expression were also
found to be colocalized with the pericellular matrix of
MSCs (Figure 3b). In contrast, fewer GFPþ Ptx3/ MSCs
were found in the wound bed (Figure 3a and b). Interest-
ingly, these cells, which were not associated with PTX3
expression, appeared to be not only poorly organized in
bundles but also scattered in the ECM (Figure 3a and b). As
expected, much lower PTX3 expression levels were detec-
ted in these skin specimens compared with control
(Figure 3a and b).
The evidence from the confocal microscopy was strongly
supported by the quantitative biochemical analysis of GFP
content in wound extracts. Western blot analysis of wound
lysates showed that skins that had been treated with Ptx3/
MSCs contained significantly lesser GFP than those treated
with control cells (0.38  0.05; fold increase  SEM over wt
MSC-treated skins), indicating a dramatic reduction in
recruited Ptx3/ MSCs at day 2 (Figure 3c and d).
Impaired pericellular fibrinolysis in Ptx3L/L MSCs
Previously, PTX3 has been shown to interact with provisional
matrix components, fibrinogen and/or fibrin, and plasmin-
ogen deposited after injury and to facilitate fibrin dissolution
(Doni et al., 2015). Thus, we sought to determine whether
this function might be altered in our animal model. For this
purpose, we employed confocal microscopy to analyze the
fibrin-rich matrix that filled the wound bed of MSC-treated
wounds and simultaneously localize PTX3 immunostaining.
At day 2, we observed a very loose fibrin matrix in the skins
treated with wt MSCs. In these samples, PTX3 colocalized
with fibrin fibers and with the ECM of numerous cells
invading the wound bed (Figure 4a). In contrast, more
abundant and dense fibrin matrix and lower levels of asso-
ciated PTX3 were detected in Ptx3/ MSC-treated woundsJournal of Investigative Dermatology (2016), Volume 136(Figure 4a). Computer-assisted fluorescence analysis of fibrin
in the wound bed of five specimens per group revealed
increased fibrin deposition in Ptx3/ MSC-treated wounds
compared with control wounds (Figure 4b).
To determine fibrin-clot degradation, we measured soluble
fibrinolysis products in wound extracts at day 2 after
wounding. We found a significant decrease in the total
amount of D-dimer, a product derived from fibrinogen, in
wounds treated with Ptx3/ MSCs compared with wt MSCs
(76.07  7.59 vs. 110.85  7.09 pg protein; mean  SEM,
respectively) (Figure 4c), indicating delayed fibrinogen
degradation and impaired clot remodeling in wounds
exposed to Ptx3/ MSCs.
Next, we assessed the pericellular fibrinolysis of Ptx3/
and wt MSCs. Because PTX3 has been recently shown to
potentiate the fibrinolysis mediated by plasmin and triggered
by the urokinase-type plasminogen activator (Doni et al.,
2015), we sought to determine whether the impairment of
plasmin-mediated signaling could affect the fibrinolytic ca-
pacity of MSCs. For this purpose, Ptx3/ and wt MSCs were
embedded in fibrin gel and their ability to induce fibrinolysis
was examined in the presence or absence of the two
plasminogen-conversion inhibitors aprotinin and plasmin-
ogen activator inhibitor-1. After 36 hours of culture, Ptx3/
MSCs showed a significantly reduced ability to digest the
fibrin clot compared with wt cells (Figure 5a and b). This
result was quantified by measuring the amount of soluble
fibrinolysis-derived products in the culture medium of
Ptx3/ and wt MSCs by ELISA (Figure 5a), and visualized by
SDS-PAGE (Figure 5b). The decrease in fibrinolysis was not
attributable to a decreased proliferation rate of Ptx3/ MSCs
because there was no significant difference between wt and
Ptx3/ MSC total cell count (data not shown). Furthermore,
fibrinolysis of MSCs was drastically abolished by the serine
Figure 4. Fibrin-rich matrix
remodeling in wounds treated with
Ptx3L/L MSCs. (a) Representative
confocal images (10) of day 2 skin
specimens (n ¼ 5), showing fibrin
immunostaining (red) in thewound bed
(wb), and colocalization of PTX3 (cyan)
with fibrin fibers. Upper panel: bundles
of PTX3-expressing cells invading the
loose fibrin matrix of wounded skins
treated with wt MSCs. Bottom panel:
confluent fibrin staining in the matrix of
Ptx3/MSC-treated wounds. Left
panels: merged images; right panels:
single markers with nucleus (blue) are
shown. C, clot; p, perilesion area.
Bar ¼ 200 mm. (b) Fibrin staining
quantification in the wound bed of
Ptx3/ and wt MSC-treated skins.
**P  0.01, Ptx3/MSC- versus wt
MSC-treated wounds. (c) ELISA of
D-dimer content in wound extracts at
day 2. *P  0.05, Ptx3/MSC versus
wt MSC-treated wounds. MSC,
mesenchymal stromal cell; PTX3,
pentraxin 3; Ptx3/, Ptx3-deficient.
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inhibitor-1 (Figure 5a and b), indicating that a plasmin-
mediated fibrinolysis mechanism occurred in our model.
Next, we analyzed whether PTX3 expression was required
for MSC migration through fibrin in vitro. For this purpose, we
tested the migratory abilities of Ptx3/ and wt MSCs in
response to CXCL12, which is an important regulator of stem
cell recruitment (Liu et al., 2011; Son et al., 2006). As shown
in Figure 6, both Ptx3/ and control MSCs efficiently
migrated toward CXCL12 on uncoated filters, with no statis-
tically significant difference. However, Ptx3/ MSCs dis-
played a significantly lower migration index through the
fibrin compared with wt MSCs (0.83  0.16 vs. 1.35  0.09,
migration index  SEM), indicating an essential role of PTX3
in fibrin invasive capacity of MSCs.
DISCUSSION
In vivo studies have shown that the administration of MSCs to
either acute or chronic wounds improves wound healing by
increasing granulation tissue formation, accelerating re-
epithelialization and stimulating angiogenesis (Alfaro et al.,
2008; Chen et al., 2008; McFarlin et al., 2006; Sasaki
et al., 2008; Wu et al., 2007). Here, using an animal model
of excisional wound healing, we show that the repairing
ability of MSCs is crucially dependent on PTX3 expression.
PTX3 is a prototypic component of the humoral arm of
innate immunity secreted in response to inflammatory stimuli
and during the wound healing process by different cell types,
including stromal cells (Bottazzi et al., 2010; Doni et al.,
2015). In this regard, here, we show that stimulation with
inflammatory cytokines induces PTX3 expression in the cul-
ture medium of BM-derived MSCs.
Recently, Doni et al., in agreement with previous reports
(Deban et al., 2010; Norata et al., 2009; Rodriguez-Grande
et al., 2014; Salio et al., 2008), have shown a nonredun-
dant protective role of PTX3 in the regulation of tissue repairand remodeling (Doni et al., 2015). PTX3 deficiency was
associated with increased clotting, excessive fibrin accumu-
lation, and delayed re-epithelialization at early time points,
followed by augmented collagen deposition, epithelial hy-
perplasia, and defective mature tissue formation at healing.
This phenotype was attributed to the lack of PTX3-dependent
facilitated plasmin-mediated fibrinolysis by tissue remodeling
cells, which is a prerequisite for appropriate tissue repair
(Doni et al., 2015). In this respect, fibrin and other provi-
sional ECM proteins are deposited after tissue injury and their
subsequent timely degradation is essential for tissue repair
(Carmeliet et al., 1994; de Giorgio-Miller et al., 2005).
On the basis of the above findings, in this study, we sought
to determine whether the lack of PTX3 in BM-derived
MSCs would similarly impair the tissue repair properties
of MSCs during wound healing. On in vitro analysis, Ptx3/
MSCs were similar to their wild-type counterpart in their
ability to grow spontaneously, undergo mesengenic differ-
entiation, and express MSC cell-surface antigens commonly
found in mesenchymal stromal cells. Furthermore, the ability
of Ptx3/ MSCs to inhibit the proliferation of activated
lymphocytes, as well as the expression of immunological
markers, was identical to that of control MSCs. However,
although treatment with wt MSCs enhanced wound repair
activity in our allogenic murine model of skin repair, in good
agreement with previous studies (Javazon et al., 2007; Sasaki
et al., 2008; Wu et al., 2007), exposure to Ptx3/ MSCs led
to a significant delay in wound closure throughout the entire
healing process. Ptx3/ MSCs had no effect on the wound
closure that was comparable to that seen in vehicle-treated
mice up to day 9 after wounding. Nevertheless, a minor ef-
fect of Ptx3/ MSCs, which needs further investigation, was
observed when compared to vehicle in the last phase of the
wound healing process. Ptx3/ MSCs failed to be recruited
to the wound bed already at day 2, because of their defective
invasion and remodeling of fibrin clot. However, becausewww.jidonline.org 297
Figure 5. In vitro pericellular fibrinolysis of Ptx3L/L MSCs. (a) ELISA of
soluble fibrinolysis products generated by Ptx3/ and wt MSCs embedded in
fibrin gel with or without APR or PAI-1. Values are expressed as O.D. mean 
SEM of triplicates. Gray column represents medium without cells. **P  0.01.
(b) Western blot analysis showing the decreased amount of fibrinolysis
products in culture of Ptx3/ MSCs and the fibrinolysis abolishment by
plasminogen-conversion inhibitors. Mouse serum (1 ml/lane) was also loaded.
a, b, and g chains of mouse fibrinogen are shown. APR, aprotinin; MSC,
mesenchymal stromal cell; PAI-1, plasminogen activator inhibitor-1; PTX3,
pentraxin 3; Ptx3/, Ptx3-deficient.
Figure 6. Migration of Ptx3L/L MSCs through fibrin. Migration ability of
Ptx3/ and wt MSCs (n ¼ 2) through uncoated () or fibrin-coated filters in
response to CXCL12 (200 ng/ml). Results are expressed as migration index 
SEM of stimulated versus unstimulated cells. The migration index was
calculated as the ratio of the number of cells migrating toward the CXCL12
gradient to the number of cells migrating toward medium alone. Five-six
randomly selected fields/insert were evaluated in three independent
experiments. **P  0.01; *P  0.05. MSC, mesenchymal stromal cell;
Ptx3/, Ptx3-deficient.
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parts in terms of immunomodulatory capacities and differ-
entiation potential, it is conceivable that soluble factor(s)
secreted by Ptx3/ MSCs in the perilesion area might have
positively influenced, in a paracrine fashion, other resident
cells responsible for the repair and/or remodeling such as
endogenous fibroblasts and/or MSCs.
In our animal model, the most important morphological
event that accompanied the impaired healing by Ptx3/
MSCs was the reduction in the granulation tissue. Never-
theless, Ptx3/ and wt MSC-treated wounds had similar
capillary density during the healing, suggesting no difference
in the angiogenesis promoted by the two MSC treatments.Journal of Investigative Dermatology (2016), Volume 136Likewise, as shown previously (Doni et al., 2015),
we observed no difference in the number of recruited in-
flammatory cells between wt and PTX3-deficient mice.
Among the different mechanisms influencing granulation
tissue formation, cell locomotion and proliferation into the
ECM appear to play a major role (Clark, 2001; Singer and
Clark, 1999). On invasion and digestion of the provisional
scaffold of fibrin, remodeling cells lay down a collagen-rich
matrix that contributes to further granulation tissue matura-
tion (Romer et al., 1996). MSCs are key elements of granu-
lation tissue (McClain et al., 1996), can be attracted by
paracrine signals, and, together with fibroblasts and
epidermal cells, favor the provisional fibrin-matrix remodel-
ing (Agis et al., 2009; Neuss et al., 2010). Our findings,
showing impaired wound closure as early as 2 days after
administration of Ptx3/ MSCs to the injury site, seem to
indicate that PTX3 affects MSC functions in the early phases
of wound healing. In this regard, as previously shown for
Ptx3-deficient cells during tissue remodeling (Doni et al.,
2015), at day 2 after wounding, Ptx3/ MSCs failed to be
recruited to the wound site and displayed a defective invasive
phenotype associated with an impaired therapeutic effect.
Because early delivery of MSCs at the site of injury is crucial
to achieve optimal repair and/or regeneration (Chen et al.,
2008), we hypothesize that a limited amount of engrafted
Ptx3/ MSCs might have been the cause of the delayed
wound closure observed in our specimens.
Furthermore, in keeping with data showing an interaction
between PTX3, fibrinogen and/or fibrin, and plasminogen,
which favored enhanced fibrinolysis (Doni et al., 2015), we
show that PTX3 deficiency in MSC treatment is associated
with increased fibrin deposition and decreased levels of D-
dimer versus control wounds. In this regard, our in vivo re-
sults indicate that a delay in clot remodeling indeed occurs in
wounds treated with Ptx3/ MSCs, indicating an impaired
ability of these cells to digest the fibrin, which likely inhibits
their ability to migrate to the injured site. The occurrence of
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remodeling cells into the wound bed.
Consistent with these findings, pericellular fibrinolysis,
in vitro, was found to be severely affected in Ptx3/ MSCs
compared with wt cells. Furthermore, fibrin digestion by
MSCs was completely prevented by the presence of
plasminogen-conversion inhibitors (aprotinin and plasmin-
ogen activator inhibitor-1), suggesting a plasmin-mediated
fibrinolysis mechanism in our model. In support of our re-
sults in vitro, at day 2, we observed colocalization of PTX3
and fibrin into the wound and in the pericellular matrix of wt
MSCs. Thus, it is likely that, in the earlier phases of wound
healing, the secretion of PTX3 around MSCs and in the
injured tissue creates, through fibrin digestion, an environ-
ment that fosters the recruitment of MSCs and other circu-
lating cells. Experiments are under way to determine whether
restoring PTX3 expression in Ptx3/MSCs can rescue MSCs-
mediated fibrinolysis in vitro.
Finally, several studies have shown that the chemokine
CXCL12 is critical for stem and/or progenitor and mesen-
chymal cell homing in injured tissues through interaction
with its cognate receptor CXCR4 (Liu et al., 2011; Son et al.,
2006). Here, we show that migration of Ptx3/ MSCs in
response to CXCL12 is significantly reduced through the
fibrin layer, providing further evidence that poor invasion of
fibrin may be the rate-limiting step in MSC movement
through the wound.
Thus, taken all together, our results suggest that the fibri-
nolysis mediated by MSC-derived PTX3 is directly related to
the dissolution of clot and fibrin-rich provisional matrix
remodeling required for the migration of these cells into the
wound, which constitutes an important prerequisite for
appropriate wound healing in our model. Moreover, it is
likely that, by creating passages into the fibrin clot, the
invading MSCs may promote the recruitment of other
remodeling cells, thereby favoring the acceleration of repair
processes such as granulation tissue maturation.
Overall, our findings support a model where PTX3 acts as a
potent promoter of tissue repair and/or remodeling exerted by
MSCs and provide further evidence of a potential therapeutic
approach for nonhealing wounds.
MATERIALS AND METHODS
Additional techniques are available in the supplementary material
online.
MSC isolation
wt and Ptx3/ MSCs were obtained from the BM of C57BL6/J wt
and Ptx3/ mice, respectively. Mononuclear cells were isolated
using Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK) and
seeded at 16  104 cells/cm2 in low glucose Dulbecco’s Modified
Eagle Medium (Lonza, Verviers, Belgium) supplemented with 20%
fetal bovine serum (Biosera, Ringmer, UK) at 37 C with 5% CO2.
After 24e48 hours, nonadherent cells were removed and adherent
cells were allowed to reach 70e80% confluence. MSCs were used
between passages 5 and 8.
GFPþ MSCs were generated through plasmid murine stem cell
virus-internal ribosomal entry site-GFP-mediated infection (Pear
et al., 1998). After 72 hours, MSCs were detached and the levelsof GFP were evaluated by FACS analysis. The percentage of
infected GFPþ cells was found to range from 94% to 96% in both
MSC lines.
Animals
wt and Ptx3/ mice, 8e12 weeks of age, were purchased from
Charles River Laboratories (Milan, Italy) and housed in individual,
ventilated, and pathogen-free cages of conventional animal facility
in the Milano-Bicocca University. Procedures involving animal
handling and care were conformed to protocols approved by the
Milano-Bicocca University in compliance with national and inter-
national law and policies. This study was approved by the Italian
Ministry of Health (approval no. 9/2011-B, issued on 19 January
2011).
Wound healing model
A full-thickness wound was created on anesthetized 129/Sv mice
(2.5% Avertin, Sigma-Aldrich, St. Louis, MO) with a sterile 8-mm-
diameter biopsy punch by excising the skin and the underlying
panniculus carnosus. A total of 106 Ptx3/ or wt MSCs were
immediately transplanted via injection and topical administration.
Briefly, 0.7  106 MSCs were subcutaneously injected around the
wound (four injections) and 0.3  106 MSCs were applied onto the
wound bed. Phosphate buffered saline and growth factor reduced
Matrigel (BD, Bedford, MA) were used as vehicles, respectively.
Wounds were daily photographed and measured by tracing the
margins onto a transparent film. The areas were obtained using
ImageJ software (version 1.44x, NIH, Bethesda, MD), and the rate of
wound closure was calculated as the ratio of the area at each time
point to the area at time 0 (immediately after wounding).
Pericellular fibrinolysis
wt or Ptx3/ MSCs (3  103/ml) were suspended in a mixture of
2.5 mg/ml plasminogen-free fibrinogen (Sigma-Aldrich). Thrombin
(1 U/ml) (Sigma-Aldrich) was then added and the suspension
immediately poured into a 24-multiwell plate on rounded glasses.
The plate was incubated for 30 minutes at 37 C to allow fibrin
polymerization. After washing with PBS2þ, fibrin cultures were
incubated with complete Dulbecco’s Modified Eagle Medium in
triplicate at 37 C. For inhibitory studies (100 kU/ml), aprotinin or
(1 mg/ml) plasminogen activator inhibitor-1 (Calbiochem-Merck,
Frankfurt, Germany) was added to the cultures. Fibrinolysis was
evaluated after 36 hours by quantifying fibrinolysis-derived products
released in the culture medium by ELISA and Western blot. Purified
rabbit polyclonal antibodyantifibrinogen (500ng/ml;Dako,Glostrup,
Denmark) was used to detect the soluble fibrinolysis-derived
products.
Statistical analysis
Results are expressed as mean  SEM. Statistical significance be-
tween groups was assessed by unpaired two-tailed Student’s t or
Mann-Whitney test with Prism software (version 4.00 for Windows;
GraphPad, Inc, La Jolla, San Diego, CA).
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